


AURA BIOSCIENCES



Developing the Next Generation of Nano-delivered Drugs



Aura™ Biosciences is developing the next generation of nano-delivered drugs. Its proprietary Nanosmart™ platform solves critical issues in drug delivery by encapsulating therapeutic agents within protein nanoparticles that mimic the structure of a virus. Nanosmart particles are engineered for precise targeting, efficient cellular uptake and scalable manufacturing.

With an initial focus in oncology, Aura's goal is to help make chemotherapeutic treatments better tolerated and more efficacious for a broader range of patients.

**Aura Biosciences is a
Tech Pioneer 2010
Award Winner by the WEF**

WORLD ECONOMIC FORUM



Technology
Pioneer
2010

Focused Development

Aura Biosciences is applying its platform Nanosmart technology to two important areas, the well-studied area of chemotherapeutics and the emerging field of RNAi.


Oncology

In addition to surgery and radiation, chemotherapy is considered the gold standard in treating oncology patients. However, traditional chemotherapy targets cells that are rapidly dividing, killing both cancerous and healthy tissue, and resulting in specific organ toxicities that can lead to serious side effects.

Aura's Nanosmart particles can encapsulate traditional drugs and use tumor-specific markers to target them to cancerous cells, releasing the drug only once inside the tumor. Nanosmart chemotherapy is being developed to improve the delivery of chemotherapeutics for a range of oncology applications, making therapies more targeted, more efficacious and helping to improve survival for millions of patients.

Targeted RNAi

Potent knockdown of a gene of interest with high sequence specificity makes RNA interference (RNAi) a promising tool to treat a variety of important diseases. However, a key issue for clinical use of these molecules is delivery. Aura Biosciences is creating nanoparticles that are optimized to mediate specific and targeted cell entry, allowing small interfering RNA (siRNA) to be delivered efficiently.



AURA BIOSCIENCES

*“...a tool to revolutionize
therapeutic targeting
and delivery.”*



Nanosmart™ Technology

Partners and Advisors

Aura Biosciences has partnered with leading European research centers to create and optimize the Nanosmart platform. Working with these prestigious institutions, Aura is rapidly advancing Nanosmart preclinical studies and expects to file an IND for its first nano-delivered drug within the next year.

With a Board of Directors and a Scientific Advisory Board comprising experts with decades of successful drug development and commercialization expertise, as well as deep technical knowledge, Aura is well positioned to capitalize on the strengths of its novel, proprietary technology as it works to revolutionize the field of nano-delivered drugs.

Contact Aura

Elisabet de los Pinos, PhD
Chief Executive Officer
epinos@aurabiosciences.com

AURA BIOSCIENCES


Aura Biosciences, Inc.

One Broadway 14th Floor
Cambridge, MA 02142 USA
T: 617.401.3360
F: 617.401.3762
www.aurabiosciences.com


Nanosmart is unique in its ability to solve critical problems in drug delivery for a wide range of therapies, offering several advantages over other delivery systems:

- **Optimal Size:** 20-30nm hollow protein nanoparticles are easily taken up by target cells
- **Targeted:** Targeting agents displayed on the surface allow Nanosmart particles to identify tumor specific receptors
- **Cellular Uptake:** Designed as a virus-like protein shell, Nanosmart is efficiently internalized through receptor-mediated endocytosis
- **Safety:** Nanosmart proteins self-degrade through natural pathways
- **Scalable:** Uniform structures are highly reproducible and designed for manufacturability and scale-up


Targeting and Internalization of Chemotherapeutic Agents



Nanosmart is designed to bind with high specificity to targeted receptors expressed only on tumor cells.



The targeting peptide identifies and binds to the receptor on the surface of the cell.



Nanosmart is internalized through receptor-mediated endocytosis. The molecule disassembles inside the cell and liberates the drug.

Images provided by
Cancer Research UK